Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.

The Drugs for Neglected Diseases initiative (DNDi) is a patients' needs-driven organization committed to the development of new treatments for neglected diseases. Created in 2003, DNDi has delivered four improved treatments for malaria, sleeping sickness and visceral leishmaniasis. A main DNDi challenge is to build a solid R&D portfolio for neglected diseases and to deliver preclinical candidates in a timely manner using an original model based on partnership. To address this challenge DNDi has remodeled its discovery activities from a project-based academic-bound network to a fully integrated process-oriented platform in close collaboration with pharmaceutical companies. This discovery platform relies on dedicated screening capacity and lead-optimization consortia supported by a pragmatic, structured and pharmaceutical-focused compound sourcing strategy.

[1]  P. Selzer.  Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates , 2009 .

[2]  E. Chatelain,et al.  Drug Discovery for Neglected Diseases: View of A Public–Private Partnership , 2009 .

[3]  Majid Ezzati,et al.  Measuring the Burden of Neglected Tropical Diseases: The Global Burden of Disease Framework , 2007, PLoS neglected tropical diseases.

[4]  E. Chatelain,et al.  Drug discovery and development for neglected diseases: the DNDi model , 2011, Drug design, development and therapy.

[5]  P. Preziosi,et al.  Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? , 2004, Nature Reviews Drug Discovery.

[6]  D. Mabey,et al.  Neglected tropical diseases. , 2010, British medical bulletin.

[7]  Peter J. Hotez,et al.  Neglected Tropical Diseases in Sub-Saharan Africa: Review of Their Prevalence, Distribution, and Disease Burden , 2009, PLoS neglected tropical diseases.

[8]  P. Hotez,et al.  “Manifesto” for Advancing the Control and Elimination of Neglected Tropical Diseases , 2010, PLoS neglected tropical diseases.

[9]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[10]  A. Francisco.  Drug development for neglected diseases , 2002, The Lancet.

[11]  A. Fairlamb,et al.  Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity , 2009, Antimicrobial Agents and Chemotherapy.

[12]  Solomon Nwaka,et al.  Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.

[13]  V. Avery,et al.  Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. , 2009, The American journal of tropical medicine and hygiene.

[14]  B. Pécoul.  New Drugs for Neglected Diseases: From Pipeline to Patients , 2004, PLoS medicine.

[15]  Frederic Bost,et al.  Informatics for neglected diseases collaborations. , 2010, Current opinion in drug discovery & development.

[16]  E. Torreele,et al.  Global framework on essential health R&D , 2006, The Lancet.

[17]  I. Gilbert,et al.  Chemical Validation of Trypanothione Synthetase , 2009, The Journal of Biological Chemistry.

[18]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[19]  F. Jennings,et al.  The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronicT. brucei infections in mice , 2004, Zeitschrift für Parasitenkunde.

[20]  David Tweats,et al.  Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness , 2010, PLoS neglected tropical diseases.

[21]  L. Conteh,et al.  Socioeconomic aspects of neglected tropical diseases , 2010, The Lancet.

[22]  S. Croft,et al.  Public-private partnership: from there to here. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  B. Nare,et al.  Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. , 2011, Future medicinal chemistry.